These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
557 related articles for article (PubMed ID: 32068069)
1. Germline Mutation in 1338 BRCA-Negative Chinese Hereditary Breast and/or Ovarian Cancer Patients: Clinical Testing with a Multigene Test Panel. Kwong A; Shin VY; Chen J; Cheuk IWY; Ho CYS; Au CH; Chan KKL; Ngan HYS; Chan TL; Ford JM; Ma ESK J Mol Diagn; 2020 Apr; 22(4):544-554. PubMed ID: 32068069 [TBL] [Abstract][Full Text] [Related]
2. Gene panel testing of 5589 BRCA1/2-negative index patients with breast cancer in a routine diagnostic setting: results of the German Consortium for Hereditary Breast and Ovarian Cancer. Hauke J; Horvath J; Groß E; Gehrig A; Honisch E; Hackmann K; Schmidt G; Arnold N; Faust U; Sutter C; Hentschel J; Wang-Gohrke S; Smogavec M; Weber BHF; Weber-Lassalle N; Weber-Lassalle K; Borde J; Ernst C; Altmüller J; Volk AE; Thiele H; Hübbel V; Nürnberg P; Keupp K; Versmold B; Pohl E; Kubisch C; Grill S; Paul V; Herold N; Lichey N; Rhiem K; Ditsch N; Ruckert C; Wappenschmidt B; Auber B; Rump A; Niederacher D; Haaf T; Ramser J; Dworniczak B; Engel C; Meindl A; Schmutzler RK; Hahnen E Cancer Med; 2018 Apr; 7(4):1349-1358. PubMed ID: 29522266 [TBL] [Abstract][Full Text] [Related]
3. Variants of cancer susceptibility genes in Korean BRCA1/2 mutation-negative patients with high risk for hereditary breast cancer. Park JS; Lee ST; Nam EJ; Han JW; Lee JY; Kim J; Kim TI; Park HS BMC Cancer; 2018 Jan; 18(1):83. PubMed ID: 29338689 [TBL] [Abstract][Full Text] [Related]
4. Multigene panel testing beyond BRCA1/2 in breast/ovarian cancer Spanish families and clinical actionability of findings. Bonache S; Esteban I; Moles-Fernández A; Tenés A; Duran-Lozano L; Montalban G; Bach V; Carrasco E; Gadea N; López-Fernández A; Torres-Esquius S; Mancuso F; Caratú G; Vivancos A; Tuset N; Balmaña J; Gutiérrez-Enríquez S; Diez O J Cancer Res Clin Oncol; 2018 Dec; 144(12):2495-2513. PubMed ID: 30306255 [TBL] [Abstract][Full Text] [Related]
5. Identifying sequence variants contributing to hereditary breast and ovarian cancer in BRCA1 and BRCA2 negative breast and ovarian cancer patients. Jarhelle E; Riise Stensland HMF; Hansen GÅM; Skarsfjord S; Jonsrud C; Ingebrigtsen M; Strømsvik N; Van Ghelue M Sci Rep; 2019 Dec; 9(1):19986. PubMed ID: 31882575 [TBL] [Abstract][Full Text] [Related]
6. Detection of Germline Mutation in Hereditary Breast and/or Ovarian Cancers by Next-Generation Sequencing on a Four-Gene Panel. Kwong A; Shin VY; Au CH; Law FB; Ho DN; Ip BK; Wong AT; Lau SS; To RM; Choy G; Ford JM; Ma ES; Chan TL J Mol Diagn; 2016 Jul; 18(4):580-94. PubMed ID: 27157322 [TBL] [Abstract][Full Text] [Related]
7. A multi-gene panel study in hereditary breast and ovarian cancer in Colombia. Cock-Rada AM; Ossa CA; Garcia HI; Gomez LR Fam Cancer; 2018 Jan; 17(1):23-30. PubMed ID: 28528518 [TBL] [Abstract][Full Text] [Related]
8. Targeted massively parallel sequencing of a panel of putative breast cancer susceptibility genes in a large cohort of multiple-case breast and ovarian cancer families. Li J; Meeks H; Feng BJ; Healey S; Thorne H; Makunin I; Ellis J; ; Campbell I; Southey M; Mitchell G; Clouston D; Kirk J; Goldgar D; Chenevix-Trench G J Med Genet; 2016 Jan; 53(1):34-42. PubMed ID: 26534844 [TBL] [Abstract][Full Text] [Related]
9. Comparison of BRCA versus non-BRCA germline mutations and associated somatic mutation profiles in patients with unselected breast cancer. Chen B; Zhang G; Li X; Ren C; Wang Y; Li K; Mok H; Cao L; Wen L; Jia M; Li C; Guo L; Wei G; Lin J; Li Y; Zhang Y; Han-Zhang H; Liu J; Lizaso A; Liao N Aging (Albany NY); 2020 Feb; 12(4):3140-3155. PubMed ID: 32091409 [TBL] [Abstract][Full Text] [Related]
10. Spectrum of germline pathogenic variants in Brazilian hereditary breast/ovarian cancer cases. Faria JP; Assumpção JG; de Oliveira Matos L; Soardi FC; Bretz GPM; Friedman E; De Marco L Breast Cancer Res Treat; 2024 Oct; 207(3):615-624. PubMed ID: 38874686 [TBL] [Abstract][Full Text] [Related]
11. Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds. Catts ZA; Baig MK; Milewski B; Keywan C; Guarino M; Petrelli N Ann Surg Oncol; 2016 May; 23(5):1729-35. PubMed ID: 26727920 [TBL] [Abstract][Full Text] [Related]
12. BRCA1 and BRCA2 Germline Mutation Analysis in Hereditary Breast/Ovarian Cancer Families from the Aures Region (Eastern Algeria): First Report. Mehemmai C; Cherbal F; Hamdi Y; Guedioura A; Benbrahim W; Bakour R; Abdelhak S Pathol Oncol Res; 2020 Apr; 26(2):715-726. PubMed ID: 30715675 [TBL] [Abstract][Full Text] [Related]
13. Extended genetic analysis and tumor characteristics in over 4600 women with suspected hereditary breast and ovarian cancer. Öfverholm A; Törngren T; Rosén A; Arver B; Einbeigi Z; Haraldsson K; Ståhlbom AK; Kuchinskaya E; Lindblom A; Melin B; Paulsson-Karlsson Y; Stenmark-Askmalm M; Tham E; von Wachenfeldt A; Kvist A; Borg Å; Ehrencrona H BMC Cancer; 2023 Aug; 23(1):738. PubMed ID: 37563628 [TBL] [Abstract][Full Text] [Related]
14. Prevalence of nonfounder BRCA1/2 mutations in Ashkenazi Jewish patients presenting for genetic testing at a hereditary breast and ovarian cancer center. Frey MK; Kopparam RV; Ni Zhou Z; Fields JC; Buskwofie A; Carlson AD; Caputo T; Holcomb K; Chapman-Davis E Cancer; 2019 Mar; 125(5):690-697. PubMed ID: 30480775 [TBL] [Abstract][Full Text] [Related]
16. Detection of Germline Variants in 450 Breast/Ovarian Cancer Families with a Multi-Gene Panel Including Coding and Regulatory Regions. Guglielmi C; Scarpitta R; Gambino G; Conti E; Bellè F; Tancredi M; Cervelli T; Falaschi E; Cosini C; Aretini P; Congregati C; Marino M; Patruno M; Pilato B; Spina F; Balestrino L; Tenedini E; Carnevali I; Cortesi L; Tagliafico E; Tibiletti MG; Tommasi S; Ghilli M; Vivanet C; Galli A; Caligo MA Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299313 [TBL] [Abstract][Full Text] [Related]
17. Multiple-gene panel analysis in a case series of 255 women with hereditary breast and ovarian cancer. Tedaldi G; Tebaldi M; Zampiga V; Danesi R; Arcangeli V; Ravegnani M; Cangini I; Pirini F; Petracci E; Rocca A; Falcini F; Amadori D; Calistri D Oncotarget; 2017 Jul; 8(29):47064-47075. PubMed ID: 28423363 [TBL] [Abstract][Full Text] [Related]
18. Retesting of women who are negative for a Lerner-Ellis J; Sopik V; Wong A; Lázaro C; Narod SA; Charames GS J Med Genet; 2020 Jun; 57(6):380-384. PubMed ID: 31784482 [TBL] [Abstract][Full Text] [Related]
19. Clinical Contribution of Next-Generation Sequencing Multigene Panel Testing for BRCA Negative High-Risk Patients With Breast Cancer. Ece Solmaz A; Yeniay L; Gökmen E; Zekioğlu O; Haydaroğlu A; Bilgen I; Özkınay F; Onay H Clin Breast Cancer; 2021 Dec; 21(6):e647-e653. PubMed ID: 33980423 [TBL] [Abstract][Full Text] [Related]
20. Prevalence of germline variants in consensus moderate-to-high-risk predisposition genes to hereditary breast and ovarian cancer in BRCA1/2-negative Brazilian patients. Gomes R; Spinola PDS; Brant AC; Matta BP; Nascimento CM; de Aquino Paes SM; Bonvicino CR; Dos Santos ACE; Moreira MAM Breast Cancer Res Treat; 2021 Feb; 185(3):851-861. PubMed ID: 33128190 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]